Regeneron drug boosts survival of Ebola to 90 percent

再生元试验药物将感染埃博拉病毒存活率提高至90%以上

2019-08-14 10:33:00 pharmamanufacturing

本文共409个字,阅读需2分钟

A new study has shown that a pair of experimental treatments could dramatically increase the chances of surviving Ebola. The two drugs, made by Regeneron, are monoclonal antibodies developed using antibodies harvested from Ebola survivors. The treatments outperformed two other drugs —Gilead’s Remdisivir and Mapp Biopharmaceutical’s ZMapp — in a recent clinical trial being conducted in the Democratic Republic of Congo (DRC). According to the researchers, 49 percent of patients taking ZMapp and 53 percent taking Remdisivir died in the study, compared to 29 percent and 34 percent of the patients taking the two Regeneron drugs. When given one of the Regeneron treatments (REGN-EB3) at an early stage of the disease, 94 percent lived. The current outbreak of Ebola in the DRC his killed at least 1,800 people and has become the second largest in history. The two Regeneron treatments will now be offered to all Ebola patients in the DRC.
一项新的研究表明,一对实验疗法可以显著增加埃博拉(Ebola)病毒存活的机会。 这两种药物由再生元(Regeneron)公司生产,是使用从埃博拉(Ebola)幸存者身上提取的抗体开发的单克隆抗体。在刚果民主共和国( DRC )最近进行的一项临床试验中,这两种药物的疗效优于其他两种药物——吉利德(Gilead)的 Remdisivior 和 Mapp Biopharma 的 ZMapp 。研究人员称,服用 ZMapp 和服用 Remdisivir 的患者中有49%死亡,而服用两种 Regeneron 药物的患者中有29%和34%死亡。在疾病早期给予再生元(Regeneron)治疗( REN-EB3)时,94%的人存活。 他目前在刚果民主共和国爆发的埃博拉(Ebola)疫情导致至少1800人死亡,成为历史上第二大疫情。两种再生元(Regeneron)疗法现在将提供给所有埃博拉(Ebola)患者在刚果民主共和国。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文